GlassScriptPhysician profile
Norman S Welch
NPI 1265439178
$24,645.63
in general payments reported to CMS, 2019-2025
75 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,597 · 2020: $4,462 · 2021: $3,384 · 2022: $3,694 · 2023: $3,025 · 2024: $3,258 · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,455 · Education: $54.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,454.56 |
| Education | $54.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,668.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,832.73 | 2019-2025 | Evenity, Tepezza, Repatha |
| Tandem Diabetes Care, INC. | $1,614.79 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $1,568.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,241.73 | 2019-2025 | |
| Abbott Laboratories | $1,165.08 | 2019-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $1,135.36 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $891.01 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $801.41 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Insulet Corporation | $783.81 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $748.72 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $743.99 | 2019-2022 | |
| Mannkind Corporation | $682.06 | 2019-2025 | Afrezza |
| Novartis Pharmaceuticals Corporation | $678.19 | 2022-2025 | |
| Medtronic, INC. | $619.90 | 2021-2024 | Minimed 780g |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $574.93 | 2019-2025 | Unithroid |
| Dexcom, INC. | $562.73 | 2020-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $390.35 | 2019-2024 | Ubrelvy, Synthroid |
| Radius Health, INC. | $385.73 | 2021-2025 | Tymlos |
| Sequel Med Tech, LLC | $361.60 | 2025 | Twiist |
| Zealand Pharma US, INC. | $305.41 | 2020-2022 | |
| Madrigal Pharmaceuticals | $282.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Ibsa Pharma INC. | $265.02 | 2019-2025 | Tirosint, Licart, Licart |
| Bigfoot Biomedical INC | $239.23 | 2022 | |
| Cequr Corporation | $207.12 | 2021-2025 | Cequr Simplicity |
| Grt US Holding, INC. | $193.58 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $170.59 | 2019-2023 | Aveed, Xiaflex |
| Becton, Dickinson and Company | $169.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $168.32 | 2019-2020 | |
| Valeritas, INC. | $157.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.34 | 2019-2024 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $146.87 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $142.72 | 2020-2022 | |
| Beta Bionics, INC. | $123.17 | 2024 | Ilet Bionic Pancreas |
| Bayer Healthcare Pharmaceuticals INC. | $120.55 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $119.18 | 2020-2025 | Isturisa |
| Chiesi USA, INC. | $115.43 | 2024-2025 | Myalept, Mycapssa, Juxtapid |
| Vistapharm, INC. | $115.42 | 2021 | |
| Alexion Pharmaceuticals, INC. | $115.42 | 2019-2023 | Strensiq |
| Medtronic Minimed, INC. | $112.42 | 2019-2020 | |
| Kvk-Tech, INC. | $110.19 | 2019 | |
| Companion Medical, INC. | $109.83 | 2019 | |
| Embecta Corp. | $95.60 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Clarus Therapeutics INC. | $92.19 | 2020-2021 | |
| Pfizer INC. | $86.58 | 2022-2023 | |
| Averitas Pharma INC. | $86.36 | 2023-2025 | Qutenza |
| Eisai INC. | $79.51 | 2019-2023 | |
| Intuity Medical INC | $78.98 | 2022 | |
| Neurocrine Biosciences, INC. | $76.91 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $69.66 | 2024-2025 | |
| Nalpropion Pharmaceuticals LLC | $68.03 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $67.32 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $61.63 | 2020-2023 | Contrave |
| Lifescan, INC. | $56.99 | 2019-2021 | |
| Shire North American Group INC | $55.91 | 2019 | |
| Ascensia Diabetes Care US INC. | $52.73 | 2019-2022 | |
| Acerus Pharmaceuticals Corporation | $49.26 | 2022 | |
| Tolmar, INC. | $48.62 | 2025 | Jatenzo |
| Ascendis Pharma Endocrinology INC | $47.75 | 2025 | Yorvipath, Skytrofa |
| Ultragenyx Pharmaceutical INC. | $41.21 | 2021-2022 | |
| Nevro Corp. | $37.84 | 2021-2024 | Senza |
| Horizon Therapeutics Plc | $36.70 | 2019-2022 | |
| Astellas Pharma US INC | $29.66 | 2024 | Veozah |
| Vivus LLC | $28.12 | 2019-2021 | |
| Daiichi Sankyo INC. | $24.35 | 2019 | |
| Genentech USA, INC. | $21.52 | 2023 | Vabysmo |
| Azurity Pharmaceuticals, INC. | $20.90 | 2023 | Adthyza |
| Nestle Healthcare Nutrition INC. | $20.35 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.95 | 2020 | |
| Kyowa Kirin, INC. | $18.89 | 2025 | |
| Antares Pharma, INC. | $17.08 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $15.76 | 2025 | Imcivree |
| Ionis Pharmaceuticals, INC. | $15.49 | 2025 | Tryngolza |
| Idorsia Pharmaceuticals US INC | $14.83 | 2023 | Quviviq |
| Aytu Biopharma, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.